Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
University Health Network, Toronto
Children's Oncology Group
Stanford University
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GlaxoSmithKline
St. Jude Children's Research Hospital
University of Wisconsin, Madison
Centre Leon Berard
Hospices Civils de Lyon
Essen Biotech
Children's Oncology Group
University Medical Center Groningen
Children's Oncology Group
National Cancer Institute (NCI)
Taproot Health
National Cancer Institute (NCI)
Hutchmed
Cellestia Biotech AG
Bayer
Karolinska University Hospital
National Cancer Institute (NCI)
City of Hope Medical Center
BTG International Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Children's Oncology Group
Celgene
Assistance Publique - Hôpitaux de Paris
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences
Novartis
SillaJen, Inc.
Rutgers, The State University of New Jersey
Eastern Cooperative Oncology Group
Valerio Therapeutics